This brand name is authorized in Austria, Brazil, Canada, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, United States, South Africa
The drug ILARIS contains one active pharmaceutical ingredient (API):
|
1
Canacinumab
UNII 37CQ2C7X93 - CANAKINUMAB
|
|
Canacinumab is a human monoclonal anti-human interleukin-1 beta (IL-1 beta) antibody of the IgG1/κ isotype. Canacinumab binds with high affinity specifically to human IL-1 beta and neutralises the biological activity of human IL-1 beta by blocking its interaction with IL-1 receptors, thereby preventing IL-1 beta-induced gene activation and the production of inflammatory mediators. |
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| Ilaris 150mg powder for solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| ILARIS Powder for solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L04AC08 | Canacinumab | L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AC Interleukin inhibitors |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: BR | Câmara de Regulação do Mercado de Medicamentos | Identifier(s): 526517110091803, 526532001155318 |
| Country: CA | Health Products and Food Branch | Identifier(s): 02460351 |
| Country: EE | Ravimiamet | Identifier(s): 1439894, 1439906, 1540268, 1741430 |
| Country: ES | Centro de información online de medicamentos de la AEMPS | Identifier(s): 109564004 |
| Country: FI | Lääkealan turvallisuus- ja kehittämiskeskus | Identifier(s): 444260 |
| Country: FR | Base de données publique des médicaments | Identifier(s): 69541570 |
| Country: GB | Medicines & Healthcare Products Regulatory Agency | Identifier(s): 350356 |
| Country: HK | Department of Health Drug Office | Identifier(s): 59736, 65635 |
| Country: IL | מִשְׂרַד הַבְּרִיאוּת | Identifier(s): 8415 |
| Country: JP | 医薬品医療機器総合機構 | Identifier(s): 3999434A1026 |
| Country: LT | Valstybinė vaistų kontrolės tarnyba | Identifier(s): 1051079, 1051080, 1063298, 1082469 |
| Country: NL | Z-Index G-Standaard, PRK | Identifier(s): 142794 |
| Country: NZ | Medicines and Medical Devices Safety Authority | Identifier(s): 14540 |
| Country: PL | Rejestru Produktów Leczniczych | Identifier(s): 100278666, 100388900 |
| Country: RO | Agenția Națională a Medicamentului și a Dispozitivelor Medicale | Identifier(s): W67327001, W67341001 |
| Country: SG | Health Sciences Authority | Identifier(s): 13866P |
| Country: TR | İlaç ve Tıbbi Cihaz Kurumu | Identifier(s): 8699504270051, 8699504270075 |
| Country: US | FDA, National Drug Code | Identifier(s): 0078-0734 |
| Country: ZA | Health Products Regulatory Authority | Identifier(s): 44/30.1/0097 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
